Antipsoriatic drug development: Challenges and new emerging therapies

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 6, Issue 1, 2012, Pages 3-21

  García Pérez, Martha Estrella ^a,b   Jean, Jessica ^a,b   Pouliot, Roxane ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Antipsoriatic therapies; Challenges; Drug discovery; Psoriasis; Psoriasis models; Satisfaction; Treatment

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIPSORIASIS AGENT; BENZODIAZEPINE DERIVATIVE; CHINESE DRUG; CLOBETASOL; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLOPAMINE; CYCLOSPORIN A; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; HERBACEOUS AGENT; HYDROXYUREA; INFLIXIMAB; KERATOLYTIC AGENT; MESOINDIGO; METHOTREXATE; NATURAL PRODUCT; PLACEBO; PSORALEN; RETINOID; RETINOID DERIVATIVE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; USTEKINUMAB; VITAMIN D DERIVATIVE;

ABDOMINAL PAIN; BONE MARROW TOXICITY; BURNING SENSATION; CHRONIC DISEASE; COMORBIDITY; DEMYELINATING DISEASE; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DYSPEPSIA; ERECTILE DYSFUNCTION; ERYTHEMA; ERYTHRODERMA; GASTRIC ULCER BLEEDING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; IMMUNOPATHOGENESIS; INFECTION; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LIVER TOXICITY; LONG TERM CARE; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARYNGITIS; PHOTOTHERAPY; PHYTOTOXICITY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; PSORIASIS; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; RHINITIS; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER; SKIN IRRITATION; STOMATITIS; TACHYPHYLAXIS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; ULCER; VERTIGO;

AGED; ANIMALS; CHILD; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG DESIGN; HUMANS; INFANT; PATENTS AS TOPIC; PATIENT SATISFACTION; PSORIASIS; TIME FACTORS;

EID: 84855862661     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221312798889248     Document Type: Review

References (169)

1. Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-20.
2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-9.
3. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol 2005; 141: 1537-41.
4. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4.
5. Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, et al. European patient perspectives on the impact of psoriasis: The EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-36.
6. Su YH, Fang JY. Drug delivery and formulations for the topical treatment of psoriasis. Expert Opin Drug Deliv 2008; 5: 235-49.
7. Papp KA. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006; 298: 7-15.
8. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: An assessment of the benefits and risks. Br J Dermatol 2005; 152: 597-615.
9. Griffiths CE, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 1-125.
10. Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: A cohort study. J Invest Dermatol 2003; 121: 252-8.
11. Yamauchi PS, Rizk D, Kormeili T, Patnaik R, Lowe NJ. Current systemic therapies for psoriasis: Where are we now? J Am Acad Dermatol 2003; 49: S66-77.
12. Gollnick HP, Dummler U. Retinoids. Clin Dermatol 1997; 15: 799-810.
13. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151 (Suppl 69): 3-17.
14. Kirby B, Griffiths CE. Novel immune-based therapies for psoriasis. Br J Dermatol 2002; 146: 546-51.
15. Ortonne JP. Clinical response to alefacept: Results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003; 17 (Suppl 2): 12-6.
16. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA 2003; 290: 3073-80.
17. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
18. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003; 48: 829-35.
19. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-55.
20. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
21. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-11.
22. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-9.
23. Baert F, Noman M, Vermeire S, Van Assche G, G DH, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
24. Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol 2005; 141: 82-4.
25. Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 1989; 21: 985-91.
26. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, et al. Relapse, rebound, and psoriasis adverse events: An advisory group report. J Am Acad Dermatol 2006; 54: S171-81.
27. Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle FO. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology 2002; 205: 213-6.
28. Tonel G, Conrad C. Interplay between keratinocytes and immune cells--recent insights into psoriasis pathogenesis. Int J Biochem Cell Biol 2009; 41: 963-8.
29. Ishida-Yamamoto A, Iizuka H. Differences in involucrin immunolabeling within cornified cell envelopes in normal and psoriatic epidermis. J Invest Dermatol 1995; 104: 391-5.
30. McKay IA, Leigh IM. Altered keratinocyte growth and differentiation in psoriasis. Clin Dermatol 1995; 13: 105-14.
31. Iizuka H, Takahashi H, Honma M, Ishida-Yamamoto A. Unique keratinization process in psoriasis: Late differentiation markers are abolished because of the premature cell death. J Dermatol 2004; 31: 271-6.
32. Bowcock AM, Krueger JG. Getting under the skin: The immunogenetics of psoriasis. Nat Rev Immunol 2005; 5: 699-711.
33. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-43.
34. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
35. Watanabe H, Kawaguchi M, Fujishima S, Ogura M, Matsukura S, Takeuchi H, et al. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J Invest Dermatol 2009; 129: 650-6.
36. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-51.
37. Finch PW, Murphy F, Cardinale I, Krueger JG. Altered expression of keratinocyte growth factor and its receptor in psoriasis. Am J Pathol 1997; 151: 1619-28.
38. van de Kerkhof PC. The evolution of the psoriatic lesion. Br J Dermatol 2007; 157: 4-15.
39. Rogalski C, Meyer-Hoffert U, Proksch E, Wiedow O. Human leukocyte elastase induces keratinocyte proliferation in vitro and in vivo. J Invest Dermatol 2002; 118: 49-54.
40. Krueger GG. Clinical features of psoriatic arthritis. Am J Manag Care 2002; 8: S160-70.
41. Christophers E, Griffiths CE, Gaitanis G, van de Kerkhof P. The unmet treatment need for moderate to severe psoriasis: Results of a survey and chart review. J Eur Acad Dermatol Venereol 2006; 20: 921-5.
42. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
43. Van Voorhees AS, Fried R. Depression and quality of life in psoriasis. Postgrad Med 2009; 121: 154-61.
44. Gupta MA, Gupta AK. Psoriasis and sex: A study of moderately to severely affected patients. Int J Dermatol 1997; 36: 259-62.
45. de Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol 2001; 144 (Suppl 58): 33-6.
46. Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat 2006; 17: 24-8.
47. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. Int J Dermatol 1993; 32: 188-90.
48. Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151: 594-9.
49. Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin 2009; 25: 2429-38.
50. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: Results from a population-based study. Arch Dermatol 2007; 143: 1493-9.
51. Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008; 159 (Suppl 2): 2-9.
52. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-44.
53. Feldman SR, Fleischer AB, Reboussin DM, Rapp SR, Bradham DD, Exum ML, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37: 564-9.
54. Carrascosa JM, Pujol R, Dauden E, Hernanz-Hermosa JM, Bordas X, Smandia JA, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: Phase II). J Eur Acad Dermatol Venereol 2006; 20: 840-5.
55. Blome C, Simianer S, Purwins S, Laass A, Rustenbach SJ, Schaefer I, et al. Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 2010; 221: 154-9.
56. van de Kerkhof PC. How to position antipsoriatic treatments? J Dermatolog Treat 2006; 17: 325-6.
57. Lamba S, Lebwohl M. Combination therapy with vitamin D analogues. Br J Dermatol 2001; 144 (Suppl 58): 27-32.
58. Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997; 37: 85-92.
59. Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003; 48: 760-7.
60. Honigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol 2001; 26: 343-50.
61. Rodewald EJ, Housman TS, Mellen BG, Feldman SR. Follow-up survey of 308-nm laser treatment of psoriasis. Lasers Surg Med 2002; 31: 202-6.
62. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988; 91: 120-4.
63. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001; 45: 649-61.
64. Wylie G, Evans CD, Gupta G. Reduced libido and erectile dysfunction: Rarely reported side-effects of methotrexate. Clin Exp Dermatol 2009; 34: e234.
65. DiGiovanna JJ, Sollitto RB, Abangan DL, Steinberg SM, Reynolds JC. Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol 1995; 131: 1263-7.
66. Lowe NJ, Wieder JM, Rosenbach A, Johnson K, Kunkel R, Bainbridge C, et al. Long-term low-dose cyclosporine therapy for severe psoriasis: Effects on renal function and structure. J Am Acad Dermatol 1996; 35: 710-9.
67. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: Scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 1999; 141: 424-9.
68. Gupta AK, Ellis CN, Siegel MT, Duell EA, Griffiths CE, Hamilton TA, et al. Sulfasalazine improves psoriasis. A double-blind analysis. Arch Dermatol 1990; 126: 487-93.
69. Puig L, Roe E, Garcia-Navarro X, Corella F, Alomar A. Efalizumab treatment of psoriasis vulgaris: A cohort study in outpatient clinical practice. Clin Exp Dermatol 2009; 34: 469-75.
70. Pugashetti R, Koo J. Efalizumab discontinuation: A practical strategy. J Dermatolog Treat 2009; 20: 132-6.
71. Gottlieb AB, Cooper KD, McCormick TS, Toichi E, Everitt DE, Frederick B, et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007; 23: 1081-92.
72. Kemta Lekpa F, Zahra K, Pautas C, Maury S, Chevalier X, Claudepierre P. Acute myeloid leukemia after infliximab: A case report. Clin Exp Rheumatol 2009; 27: 999-1000.
73. Caviglia R, Boskoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: Safety and tolerability issues. Expert Opin Drug Saf 2008; 7: 617-32.
74. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009; 36: 898-906.
75. Horneff G, Ebert A, Fitter S, Minden K, Foeldvari I, Kummerle-Deschner J, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford) 2009; 48: 916-9.
76. Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 2007; 26: 6-14.
77. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
78. Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol 2008; 26: 380-6.
79. Smith KC, Lebwohl M. Topical antipsoriatics. Skin Therapy Lett 2000; 5: 1-2.
80. Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: Results from a European survey. J Eur Acad Dermatol Venereol 2005; 19 (Suppl 3): 2-6.
81. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487-98.
82. Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009; 160: 438-41.
83. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581-3.
84. Ciocon DH, Horn EJ, Kimball AB. Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only: Results of the 2005 Spring US National Psoriasis Foundation Survey. Am J Clin Dermatol 2008; 9: 111-7.
85. Gokdemir G, Ari S, Koslu A. Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol 2008; 22: 330-5.
86. Di Bonaventura M, Wagner S, Waters H, Carter C. Treatment patterns and perceptions of treatment attributes satisfaction and effectiveness among patients with psoriasis. J Drugs Dermatol 2010; 9: 938-44.
87. Poulin Y, Papp KA, Wasel NR, Andrew R, Fraquelli E, Bernstein G, et al. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol 2010; 49: 1368-75.
88. Tan J, Stacey D, Fung K, Barankin B, Bissonnette R, Gulliver W, et al. Treatment decision needs of psoriasis patients: Crosssectional survey. J Cutan Med Surg; 14: 233-9.
89. Ben-Arye E, Ziv M, Frenkel M, Lavi I, Rosenman D. Complementary medicine and psoriasis: Linking the patient's outlook with evidence-based medicine. Dermatology 2003; 207: 302-7.
90. Tan, J.H. Psoriasis treatment. US20040071791 (2004).
91. Moady, M. Antipsoriatic compositions comprising an asphodelus extract, methods of making and method of using. USRE39199 (2006).
92. Pouliot, Y., Gauthier, S., Lamiot, E., Aattouri, N., Juneau, C. Composition for treating psoriasis. US20060127493 (2006).
93. Miketin, B. Method for treatment of skin disorders. US7195781 (2007).
94. Shaish, A., Dror, H., Shoshana, G. Methods for treating psoriasis. WO2011070568 (2011).
95. Müller, K., Wolfgang, W., Gürster, D., Peters, S., Née, P. 10-Substituted 1,8-dihydroxy-9(10H) anthracenone pharmaceuticals. US6127426 (2000).
96. Pellicia, M.T., Gianella, A., Gianella, J. Use of resveratrol for the treatment of exfoliative eczema, acne and psoriasis. US20010056071 (2001).
97. Wang, L., Liu, X.M., Mo, L., Mencher, S. K, McCarron, JP. Methods of treating an inflammatory related disease. US7582670 (2009).
98. Tas, S., Oktay, A. Use of cyclopamine in the treatment of psoriasis. US7605167 (2009).
99. Tas, S., Oktay, A. Pharmaceutical composition comprising a corticosteroid and a specific inhibitor of hedgehog/ smoothened signaling. US7629352 (2009).
100. Schafer, P.H., Muller, G.W., Rohane, P.E.W. Methods for the treatment of psoriasis or psoriatic arthritis using cyclopropyl-N-(2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl) ethyl]-3-oxoisoindoline-4-yl) carboxamide. US20090239926 (2009).
101. Glick, G.D. Benzodiazepine compositions for treating epidermal hyperplasia and related disorders. US7683046 (2010).
102. Chartash, E.K., Barchuk, W.T., Paulson, S.K., Valdes, J.M., Kimball, A.B. Methods of treating plaque psoriasis. US7776331 (2010).
103. Johansen, B., Anthonsen, M., Sjursen, W., Holmeide, A.K., Skattebol, L. Use of polyunsaturated ketones for the treatment of psoriasis. US20100152293 (2010).
104. Buck, J., Levin, L., Zippin, J. Method to treat psoriasis and other hyperproliferative skin disorders. WO2010096830 (2010).
105. Chen, G., Webster, M., Li, J., Hu, K., Zhu, J., Liu, W. Antiinflammatory and psoriasis treatment and protein kinase inhibition by hydroxystilbenes and novel stilbenes derivatives and analogues. US7868047 (2011).
106. Fishman, P. Pharmaceutical composition comprising A3 adenosine receptor agonist (IB-MECA/CF-101) for treatment of psoriasis. WO2011027348 (2011).
107. Dejovin, J.A. Use of alpha 2 adrenergic receptor agonist for treating or preventing psoriasis. WO2011075267 (2011).
108. Beckman, R., Johnson-Leger, C. Humanized antibodies against IL-22 RA. WO2011061119 (2011).
109. Chu, K., Wang, C. Composition for treating psoriasis. US20110091472 (2011).
110. Babu, R.S., Wada, Y., Shen, J., Nguyen, W. Topical formulations for the treatment of psoriasis. US20110098267 (2011).
111. Hrenn A, Steinbrecher T, Labahn A, Schwager J, Schempp CM, Merfort I. Plant phenolics inhibit neutrophil elastase. Planta Med 2006; 72: 1127-31.
112. Meyer-Hoffert U, Wingertszahn J, Wiedow O. Human leukocyte elastase induces keratinocyte proliferation by epidermal growth factor receptor activation. J Invest Dermatol 2004; 123: 338-45.
113. Zarmanian, I., Rogan-Grgas, J. Pharmaceutical compositions for treating psoriasis. US6693100 (2004).
114. Fishman P, Bar-Yehuda S, Ardon E, Rath-Wolfson L, Barrer F, Ochaion A, et al. Targeting the A3 adenosine receptor for cancer therapy: Inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res 2003; 23: 2077-83.
115. Fishman, P., Cohn, I. A biological marker for psoriasis. WO2008056361 (2008).
116. Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L, Khalili K. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene 2002; 21: 4060-4.
117. Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, et al. The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther 2006; 8: R33.
118. Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, et al. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 2005; 32: 469-76.
119. Glorgio, E. Endipalene formulations in the treatment of psoriasis. US20110105624 (2011).
120. Dascalu, A. Triptans for the treatment of psoriasis. WO2011048496 (2011).
121. Williams CH, Hong CC. Multi-step usage of in vivo models during rational drug desing and discovery. Int J Mol Sci 2011; 12: 2262-74.
122. Guttman-Yassky E, Krueger JG. Psoriasis: Evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol 2007; 157: 1103-15.
123. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
124. Lesko LJ, Atkinson AJ, Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001; 41: 347-66.
125. Rashmi R, Rao KS, Basavaraj KH. A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol 2009; 34: 658-63.
126. de Vlam K, Gottlieb AB, Fitzgerald O. Biological biomarkers in psoriatic disease. A review. J Rheumatol 2008; 35: 1443-8.
127. Mestas J, Hughes CC. Of mice and not men: Differences between mouse and human immunology. J Immunol 2004; 172: 2731-8.
128. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.
129. Mizutani H, Yamanaka K, Konishi H, Murakami T. Animal models of psoriasis and pustular psoriasis. Arch Dermatol Res 2003; 295 Suppl 1: S67-8.
130. Schon MP. Animal models of psoriasis: A critical appraisal. Exp Dermatol 2008; 17: 703-12.
131. [Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003; 112: 1571-80.
132. Dam TN, Kang S, Nickoloff BJ, Voorhees JJ. 1Alpha, 25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J Invest Dermatol 1999; 113: 1082-9.
133. Petersen TK. In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery. Basic Clin Pharmacol Toxicol 2006; 99: 104-15.
134. Gudjonsson JE, Johnston A, Dyson M, Valdimarsson H, Elder JT. Mouse models of psoriasis. J Invest Dermatol 2007; 127: 1292-308.
135. Boehncke WH. The psoriasis SCID mouse model: a tool for drug discovery? Ernst Schering Res Found Workshop 2005: 213-34.
136. Boguniewicz M, Leung DY. 10. Atopic dermatitis. J Allergy Clin Immunol 2006; 117: S475-80.
137. Farshidi A, Sadeghi P. Successful treatment of severe refractory atopic dermatitis with efalizumab. J Drugs Dermatol 2006; 5: 994-8.
138. Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: A stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol 2007; 143: 1175-9.
139. Opmeer BC, Heydendael VM, deBorgie CA, Spuls PI, Bossuyt PM, Bos JD, et al. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: A preference assessment based on clinical scenarios with trade-off questions. J Clin Epidemiol 2007; 60: 696-703.
140. Sims J. Assessment of biotechnology products for therapeutic use. Toxicol Lett 2001; 120: 59-63.
141. Brown RA, Sethi KK, Gwanmesia I, Raemdonck D, Eastwood M, Mudera V. Enhanced fibroblast contraction of 3D collagen lattices and integrin expression by TGF-beta1 and-beta3: Mechanoregulatory growth factors? Exp Cell Res 2002; 274: 310-22.
142. ICH Harmonized Tripartite Guideline. Safety evaluation of biotechnology derived pharmaceuticals S6 (R1). Center for Biologics Evaluation and Research. Available at: http: //www.ich.org/ fileadmin/Public_Web_Site/ICH_Products / Guidelines/ Safety/S6_R1/Step4/S6_R1_Guideline.pdf. (Accessed on: October 1, 2011).
143. Serabian MA, Pilaro AM. Safety assessment of biotechnologyderived pharmaceuticals: ICH and beyond. Toxicol Pathol 1999; 27: 27-31.
144. Black LE, Green JD, Rener J, Dayan A, Cavagnaro JA, Spindler P, et al. Safety evaluation of immunomodulatory biopharmaceuticals: Can we improve the predictive value of preclinical studies? Hum Exp Toxicol 2000; 19: 205-7.
145. Cavagnaro JA. Preclinical safety evaluation of biotechnologyderived pharmaceuticals. Nat Rev Drug Discov 2002; 1: 469-75.
146. European Medicines Agency. Committee for medicinal products for human use. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. Available at http: //www.ema.europa.eu/docs/en_GB/document_library/Scientific_gu ideline/2009/09/WC500003329.pdf (Accesed on: October 1, 2011)
147. van de Kerkhof PC. Options for the treatment of psoriasis: A multifactorial approach. Clin Dermatol 2008; 26: 419-23.
148. Haider AS, Lowes MA, Gardner H, Bandaru R, Darabi K, Chamian F, et al. Novel insight into the agonistic mechanism of alefacept in vivo: Differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol 2007; 178: 7442-9.
149. Kimball AB, Kupper TS. Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology. Clin Dermatol 2008; 26: 554-61.
150. Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620-8.
151. Menter MA, See JA, Amend WJ, Ellis CN, Krueger GG, Lebwohl M, et al. Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol 1996; 34: 315-21.
152. Beylot C, Puissant A, Bioulac P, Saurat JH, Pringuet R, Doutre MS. Particular clinical features of psoriasis in infants and chidren. Acta Derm Venereol Suppl (Stockh) 1979; 87: 95-7.
153. Marcoux D, Prost Y. Pediatric psoriasis revisited. J Cutan Med Surg 2002; 6: 22-8.
154. Oranje AP, Marcoux D, Svensson A, Prendiville J, Krafchik B, Toole J, et al. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol 1997; 36: 203-8.
155. Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol 1991; 25: 1166-9.
156. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev 2002; 54 (Suppl 1): S77-98.
157. Katare OP, Raza K, Singh B, Dogra S. Novel delivery system in topical treatment of psoriasis: Rigors and vigors. Indian J Dermatol Venereol Leprol 2010; 76: 612-21.
158. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-30.
159. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
160. Dreiher J, Weitzman D, Cohen AD. Psoriasis and osteoporosis: A sex-specific association? J Invest Dermatol 2009; 129: 1643-9.
161. Dreiher J, Weitzman D, Shapiro J, Davidovici B, Cohen AD. Psoriasis and chronic obstructive pulmonary disease: A case-control study. Br J Dermatol 2008; 159: 956-60.
162. Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol 2009; 129: 1601-3.
163. Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, et al. A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. J Am Acad Dermatol 2009; 61: S1-46.
164. Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: A randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003; 72: 407-11.
165. Reid DC, Kimball AB. Clobetasol propionate foam in the treatment of psoriasis. Expert Opin Pharmacother 2005; 6: 1735-40.
166. Jean J, Lapointe M, Soucy J, Pouliot R. Development of an in vitro psoriatic skin model by tissue engineering. J Dermatol Sci 2009; 53: 19-25.
167. Jean J, Soucy J, Pouliot R. Effects of retinoic acid on keratinocyte proliferation and differentiation in a psoriatic skin model. Tissue Eng Part A 2011; 17: 1859-68.
168. Trapasso E, Cosco D, Celia C, Fresta M, Paolino D. Retinoids: New use by innovative drug-delivery systems. Expert Opin Drug Deliv 2009; 6: 465-83.
169. Dubertret L. Retinoids, methotrexate and cyclosporine. Curr Probl Dermatol 2009; 38: 79-94.